724615904US

20. A Other items or information: Unexecuted Declaration and Power of Attorney

FILING BY "EXPRESS MAIL" UNDER 37

Form PTO-1390-MOD U. S (REV 10-96)	Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER ON/4-32910A							
TRANSMITTAL LETTER TO	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)								
DESIGNATED/ELECTED O	10/549250								
	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED							
INTERNATIONAL APPLICATION NO. PCT/EP2004/002616	12 March 2004 (12.03.04)	14 March 2003 (14.03.03)							
TITLE OF INVENTION		ODLACTIC DISEASES INFLAMMATORY							
2,4-DI (PHENYLAMINO) PYRIMIDINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS									
APPLICANT(S) FOR DO/EO/US									
GARCIA-ECHÉVERRIA ET AL.									

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay 3. examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1) A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority 4. date. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) 5. a. \square is transmitted herewith (required only if not transmitted by the International Bureau). has been transmitted by the International Bureau. (See Form PCT/IB/308) c. is not required, as the application was filed in the United States Receiving Office (RO/US). A translation of the International Application into English (35 U.S.C. 371(c)(2)). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)). are transmitted herewith (required only if not transmitted by the International Bureau). have been transmitted by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)). A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11. to 16. below concern document(s) or information included. 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. A change of power of attorney and/or address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4). A second copy of the English language translation of the International application under 35 U.S.C. 154(d)(4).

U.S. APPLIC	CATION NO	ATION NO. II KAMMOOO 37 PR 25 0 INTERNATIONAL APPLICATION NO. PCT/EP2004/002616 ON/4-329												
The follo	wing fe	es are su	ıbmitted:									ULATIC	NS PTO US	E
21. 🔯	∛l Basi	c nationa	ıl fee					J	C17 Re	c'd PC	rÿ¥T	0 1	2 SE	P 2005
22. Examination Fee If International preliminary examination report was prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4) \$														
. ⊠ All other situations														
23. Search fee ☐ If Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority \$ ☐ If International Search Report was prepared and provided to the Office \$400 ☐ All other situations									\$400					
						21, 22 AND 23 =					\$	900		
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper of thereof.									nce listing of paper o	or comp r fractio	outer n			
Total SI	heets	Extra	sheets			ach additional 50 or f d up to a whole num			RA	E .				
180 -	100 =	80	/50 =		(2	, ,	7	(\$	250	\$	500		
Surchard	ge of \$1	30 for fu	rnishina tha	oath of	declar	ration later than	∃ 30	-			\$,,		
months f	from the		claimed pri	ority date	e (37 (CFR 1.492(e)).					"			
	CLAIMS			ER FILE		NUMBER EXTR	<u>A</u>		RATE		_			
Total cla			21		20 =	1		X	<u> </u>	50	\$	50		
Independ			2		. 3 =	0		<u> </u>	\$ \$	200	\$			
MULTIP	LE DEF	ENDEN	T CLAIM(S)	(if appii	cable		OVE			360 ONS =	\$	1,450	~	
TOTAL OF ABOVE CALCULATIONS = Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).							\$	1,450						
11100 (110	10 07 0	7 1 1.0,	1.27, 1.20).						SUBT	OTAL =	\$	1,450		
Processing fee of \$130 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).								\$						
						T	OTAL	. N/	ATIONAL	FEE =	\$	1,450		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +							mpanied +	\$						
TOTAL FEES ENCLOSED =							\$	1,450						
											be: r	nount to	\$	
	<u> </u>					4	6	:				charged	\$	
a. □ b. ⊠	A check in the amount of \$ to cover the above fees is enclosed. Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1,450 to cover the above fees. A													
c. 🛛	duplicate copy of this form is enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to													
	Deposit Account No. 19-0134 in the name of Novartis.													
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.											7(a)			
Send all correspondence to the address associated with Customer No. 001095, which is currently: Lydia T. McNally						ll.								
(One He	ite Intelle alth Plaz	ctual Prope a, Building J 07936-10	104			Lydia Attorn Reg. 1 (862)	ey to No. 3	r Applican 6,214	ts	ð			